Episode Details

Thanks for tuning into another episode of The BioHub, we were delighted to welcome on Micah Mackison who serves as the Chief Executive Officer of Vico Therapeutics, a company blazing trails in genetic neurology with RNA-based medicines. Since taking the helm in August 2022, Micah has been leading Vico’s drive to translate novel oligonucleotide RNA-modulating therapies from the lab into clinical trials, particularly in disorders like Huntington’s disease and spinocerebellar ataxia. Before Vico, Micah served as Chief Business Officer and EVP of Strategy & Corporate Development at Locanabio, a gene therapy company targeting neurological disease, where he played a key role in strategy setting, capital-raising, and organizational development. Prior roles include senior leadership in corporate development and strategy at Assembly Biosciences; heading new ventures and corporate strategy in neuroscience at Lundbeck; and before that, leading M&A & corporate development at Ovation Pharmaceuticals — the company that launched the first product for Huntington’s disease. Early in his career, he worked in finance with Eli Lilly and Pfizer. At Vico, Micah is particularly focused on advancing their lead candidate VO659, an antisense oligonucleotide that aims to slow or halt progression in CAG-repeat neurological diseases, and on growing the company’s proprietary VICOMER™ platform for RNA modulation